Everest Medicines Ltd. (HK:1952) has released an update.
Everest Medicines Limited has released its unaudited interim financial results for the first half of 2024, reviewed by both the audit committee and auditors PricewaterhouseCoopers. The results are available on the company’s and Hong Kong Stock Exchange’s websites, with printed versions to be distributed by the end of September 2024. This announcement ensures compliance with the Hong Kong Stock Exchange’s listing rules for interim result disclosures.
For further insights into HK:1952 stock, check out TipRanks’ Stock Analysis page.
